IDXX

IDEXX Laboratories Inc

Add to Watchlist

Advanced Chart

514.610

-4.1(-0.790%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

523.050

Open

523.050

VWAP

515.83

Vol

329.56K

Mkt Cap

41.39B

Low

513.250

Amount

170.00M

EV/EBITDA(TTM)

32.94

Total Shares

82.59M

42.16B

EV/OCF(TTM)

43.54

P/S(TTM)

10.83

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.04B

+8.61%

2.836

+8.24%

1.05B

+7.65%

3.087

+10.24%

1.07B

+6.35%

3.291

+8.97%

Estimates Revision

The market is revising Upward the revenue expectations for IDEXX Laboratories, Inc. (IDXX) for FY2025, with the revenue forecasts being adjusted by 0.69% over the past three months. During the same period, the stock price has changed by 26.55%.

Revenue Estimates for FY2025

Revise Upward

+0.69%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.67%

In Past 3 Month

Stock Price

Go Up

+26.55%

In Past 3 Month

8 Analyst Rating

6.13% Upside

Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 546.14 USD with a low forecast of 475.00 USD and a high forecast of 625.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

3 Hold

0 Sell

Moderate Buy

6.13% Upside

Current: 514.610

Low

475.00

Averages

546.14

High

625.00

6.13% Upside

Current: 514.610

Low

475.00

Averages

546.14

High

625.00

Leerink

Daniel Clark

Outperform

maintain

$580 -> $600

2025-07-17

New

Reason

Leerink

Daniel Clark

Price Target

$580 -> $600

2025-07-17

New

maintain

Outperform

Reason

Leerink analyst Daniel Clark raised the firm's price target on Idexx Laboratories to $600 from $580 and keeps an Outperform rating on the shares. The firm continues to like Idexx's setup over the next few years and raises its 12-month price target following channel checks and its semiannual veterinarian survey.

Stifel

Hold

maintain

$510 -> $540

2025-07-02

Reason

Stifel

Price Target

$510 -> $540

2025-07-02

maintain

Hold

Reason

Stifel raised the firm's price target on Idexx Laboratories to $540 from $510 and keeps a Hold rating on the shares. The firm's checks on Medical Technology & Supplies were "poor," with deteriorating longitudinal metrics across several variables, the analyst tells investors in a research note. The firm thinks Idexx needs cancer diagnostics and inVue traction, as well as an improvement in visits.

Stifel

Jonathan Block

Hold

maintain

$460 -> $510

2025-05-19

Reason

Stifel

Jonathan Block

Price Target

$460 -> $510

2025-05-19

maintain

Hold

Reason

Stifel analyst Jonathan Block raised the firm's price target on Idexx Laboratories to $510 from $460 and keeps a Hold rating on the shares after revisiting Q1 earnings reports across the analyst's Animal Health, Dental and Sleep Apnea coverage.

Stifel

Jonathan Block

Hold

Maintains

$450 → $420

2025-04-14

Reason

Stifel

Jonathan Block

Price Target

$450 → $420

2025-04-14

Maintains

Hold

Reason

Piper Sandler

David Westenberg

Hold

Maintains

$435 → $510

2025-02-10

Reason

Piper Sandler

David Westenberg

Price Target

$435 → $510

2025-02-10

Maintains

Hold

Reason

Piper Sandler raised the firm's price target on Idexx Laboratories to $510 from $435 and keeps a Neutral rating on the shares. The firm cites updated estimates and moving forward of its estimate year to 2026 from 2025.

B of A Securities

Michael Ryskin

Hold

Maintains

$475 → $535

2025-02-04

Reason

B of A Securities

Michael Ryskin

Price Target

$475 → $535

2025-02-04

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX.O) is 41.04, compared to its 5-year average forward P/E of 51.81. For a more detailed relative valuation and DCF analysis to assess IDEXX Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

51.81

Current PE

41.04

Overvalued PE

64.36

Undervalued PE

39.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

36.13

Current EV/EBITDA

29.30

Overvalued EV/EBITDA

44.70

Undervalued EV/EBITDA

27.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

11.35

Current PS

9.86

Overvalued PS

13.84

Undervalued PS

8.86